

A next generation health information company



Our Mission

Enable physicians and patients to more seamlessly engage the digital universe of data, knowledge and understanding to better diagnose, treat, and prevent disease

A Spinout of the Mount Sinai Health System

- Mount Sinai Health System is one of the largest and most respected academic medical centers and health systems in the United States, featuring 7 hospital campuses and Icahn School of Medicine. Mount Sinai has more than 6,000 physicians and 140 ambulatory practice locations throughout the Tri-State Area.
- Icahn School of Medicine is an international leader in medical and scientific training, biomedical research, and patient care, featuring more than 5,000 faculty
- Mount Sinai has made a substantial investment toward the future of genetic research and diagnostics and are committed to developing next generation treatments



Our Science

Now Ranked 4th in the Country for Medical Research in Genetics

Institution by Rank	Change in Ranking from 2011
Baylor College of Medicine	$1 \rightarrow 1$
Washington University	$2 \rightarrow 2$
Stanford University	$4 \rightarrow 3$
Icahn School of Medicine	31
North Carolina, Chapel Hill	$6 \rightarrow 5$
Harvard Medical School	9 6
University of Washington	7 ← 3
University of Miami MS	20
Columbia University	13 9
Duke University	5 ← 10
Johns Hopkins University	24
University of Pittsburgh	12 - 10
Yale University	26
University of Chicago	7 🔶 14

Sema4 has grown rapidly over the past 5 years





Advanced technologing have aiger in the digital universe that is fundamentally transforming life as we know it

people watched the 'League of Legends' World Championship (more than the World Series or NBA Finals)

Advances in DNA sequencing technologies have now added to this explosion



Single cell, real-time, continuous? These types of rapid technology advances are delivering massive scales of data around individuals, that if appropriately integrated, can dramatically alter our ability to predict disease risk or diagnose, treat, or even prevent disease



Mobile + Social Networks



The Cloud



Big Data Analytics



Next-Gen Genomics



FUR YOUR EYES ONLY CIA 'implanted microphones into CATS' in a bizarre attempt to spy on Russia



Advanced Materials



3D Printing



The "Internet of Things"

On the molecular side, significant cohorts profiled at an unprecedented depth





Providing for the first time extensive maps of disease



The thickness of the edges between the tissue and the disease reflect how frequently a disease-causing gene is shared between pairs of diseases and tissues.

Complementing the molecular dimensions is the "Exposome", the newest "Omic"



"The totality of environmental exposures throughout a lifetime"

-Analogous to the Genome

Bob Wright/Mount Sinai

App enabled use of Geographical Information Systems for the "External Exposome"



Air Temperature/Climate



Social Media Content

Bob Wright/Mount Sinai



Exposure to green, natural areas

Access to Healthy Foods





Traffic patterns





The value of a more completely phenotyped and molecularly profiled population



Using EHR data, diabetic patients organized into 3 distinct groups representing different severity, comorbidities and genetic components



Subtype 1:

- More likely to suffer from blindness and vision defects
- Grouping genetically supported

Subtype 2:

- Greater risk of infections and cancer
- More immune deficient

Subtype 3:

- Higher blood pressure, blood clots, more metabolic syndrome like
- Grouping genetically supported

We can go further to integrate these different dimensions of data to build models



Host Molecular(DNA, RNA, Proteins) 📃 Microbiome Molecular 📃 Clinic

Clinical (EMR)



Simulation on these models enables in silico perturbations the elucidate information flow



Sema4: New MS effort pushing an information driven approach to reinventing medicine





Pioneering today the application of these individual patient trajectories in cancer

Patient tumor and germline are profiled, key drivers identified, tumor constructed in avatar models, those models taken through HTS for identification of drug cocktail



Medical systems of the future...

Largest car company in the world owns no cars (founded 2009)





> 200,000 drivers in US > 1,000,000 drivers world wide

Largest hotel chain in the world owns no hotels (founded in 2008) airbnb Total Guests 60,000,000+ 34,000+ 88 1,400+ 190+ 2.000.000+



THE PROBLEM: We do not have the scale of content needed to build these models to realize this vision



Which translates into being able to see far more of the clinically actionable genome for much less cost





Why do we believe we can growth hack up to big numbers via genetic testing? Not only do we have significant efforts in predictive modeling, but we are leaders in genomic testing

- MGTL offers comprehensive testing for numerous genetic disorders through the following 4 panels:
 - Standard Pan-ethnic Panel (4 Disorders)
 - High Frequency Pan-ethnic Panel (10 Disorders)
 - Comprehensive Jewish Panel (96 Disorders) prevalent in Ashkenazi, Sephardic and/or Mizrahi Jews
 - Expanded Carrier Screening Panel, NGS-based
 + companion assays; pan-ethnic (281
 Disorders)
- Highly competitive vs. commercial competitors (Counsyl, Good Start, Integrated, Recombine)
- Major reference partners onboard

1004443 al Retardation, and Seizure tel 8 Deficiency (CP78) hards Minrahi Discovers (38 all Jewish groups (100 Custo Educatio (CETR Fener (MEFV) Fragle X Syndrome (FMP) Type & KLAU Thomas and the second sec Deficiency (PWH) Retritis Pigmentose 28 (FAMIESA) Smith-Lenie Optiz Syndrome (DHCR2) Spinul Mascular Abophy CAMM Tay-Sachs Disease (HEXA) Wison Disease (ATP78) r Dyndrome Type 64 (USHE)4

Comprehensive, pan-ethnic screening panel (281 disorders)

Milestone connection between diagnostic testing and information system





General surveillance and managing wellness



Managing pregnancy and postnatal journey

Creating a feedback loop to continually refine test interpretations and expand test utility



Existing Customer Journey



MAJOR TAKEAWAY

An anxiety-inducing rollercoaster experience with too many variations.

- Patients bounce back and forth across stakeholders almost at every step.
- Inconsistent service throughout, relying too much on individual interactions.
- GCs are overloaded with logistics and repetitive tasks that steal time from actual counseling.

New Customer Journey



Current Journey

eGC Journey





Please select your role to launch the demo

PATIENT



Sarah Wagner Patient

COUNSELOR



Genetic Counselor Mount Sinal

SCENARIO Upon her Carrier Screening test, Sarah Wagner (patient) has scheduled a Live Consult session with Janelle McCarthy (genetic counselor).

This prototype demonstrates the key aspects of the Live Consult session.





2/17/17

Stephanie Arnold

Profile Settings	Tests	
Tests	Expanded Carrier Screening Test Test Date: 1/31/17 Referring Physician: Robert Smith, M.D.	• NEW
	Sample Received	2/1/17
	Analysis Complete	2/15/17
	Consult.	2/17/17, 10 am
	2 Results Available	2/17/17

View Results





Patient Phone: 55			Session In Progress	• 00:22	End Consult
	NextSt	ep™			
		Summary	T.		
	V REDUCE RISK				
	No variants w	ere detected in 279	Genes.		
	VARIANT FOUND				
	Condition 1 -	Lorem Ipsum			
	Condition 2 -	Lorem Ipsum			
-					

to be a second of


actions.com/#





(50f6)



Section .

ons.com/#

Sarah Wagner — Resend Invite Patient Phone: 555-555-5555	Session in Progress			
Recommendation	is & Next Steps			
NEXT	 Test your partner Testing your partner will check if he is also a carrier of Tay-Sechs and Mediterranian Fever. Testing will give you a more conclusive understanding of your risk. 			
AFTER PARTNER TESTING	 Consideration of residual risk after a negative carrier screen is recommended, especially in the case of a positive family history for a specific disorder. 			
DURING PREGNANCY	 Fetal DNA Test Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ration. 			
AFTER BIRTH	 Carrier Testing if you and your partner carry a condition likely to affect your child we recommend testing your child after birth so they can. 			
Mount				

teractions.com/#



Your Sema4 account.

Access to your results, records and health. All in one place.

	Log In _{Email} Dr.Smith@mssm.edu	
Need to create an account?	Password	
Create	Forgot Password?	
	Log In	

sema4	For Pregnancy	For Oncology	For Providers	Our Story	Contact Us
123 Broad Street New York, NY 10029 123-456-7890	Register Sample Diseases Screened Information Sheet	Partnerships Research	Test Catalog Ordering Tests Testing Labs	Media Leadership New York Lab	Jobs FAQ
	Provider Info	Test Catalog	Customer Service	Blog	









Welcome back, Jane

Your CarrierCheck results are ready.

This report will help you understand what your results mean and give you some suggestions on what to do next.

What We Found

We analyzed your DNA to see if you are a carrier of gene variants (or changes) associated with 65 inherited conditions. Carriers are usually healthy, but may have an increased risk of having a child with a genetic disease.

(+) Carrier	
1 condition	64 conditions
You tested positive for one of the gene variants	You tested negative for most of the gene
that we screened for.	variants that we screened for.





Tests Knowledge Base Preferences

Dr. John Smith

Tests

Search for Name, Test. Status Q							Order 🕂	
Name 🐱	DOB 🖌	Sample 🗸	Test 🗸	Date 🗸	Physician 👻	Status 🗸	Results Viewed 🗸	Consult 🐱
Abigail Smith	1/12/83	23802830	Next Step	1/12/16	Smith, John	Final	Y	Y
John Adams	1/8/80	83092803	Next Step	1/12/16	Smith, John	Final	Ν	۷
George Hoover	2/12/78	10838275	Next Step	1/12/16	Smith, John	Final	Ŷ	Y
Katherine Washington	1/12/82	66729300	Next Step	1/12/16	Smith, John	Final	Y.	Ŷ
Duincy Cleveland	3/24/84	20814423	Next Step	1/12/16	Smith, John	In Progress	N	N
Eleanor Smith	11/18/75	11390872	Next Step	1/12/16	Smith, John	Final	¥.	Y

Patient	Sample		Referring Doctor
Patient Name:XXXXDate of Birth:6/19/1980Reference #:3441385Indication:Carrier TestinTest Type:Full Pan-Ethni	Lab #: Date Collected: Date Received:	Blood 1410970 7/16/2016 7/16/2016 7/16/2016	Referring: XXXXZXXXX, M.D. Park Avenue New York, NY 10128 Fax#: XXX-XXX-XXXX

Results Summary

POSITIVE for Smith-Lemli-Opitz Syndrome One copy of the c.964-1G>C mutation

Negative for all other mutations tested in the other 280 diseases

Recommendations

Testing the partner for this condition and genetic counseling

Interpretation Summary

This patient carries one copy of the DHCR7 c.964-1G>C mutation and is at least a carrier for Smith-Lemil-Opitz syndrome. The negative results for the other gene mutations do not completely exclude the possibility that this patient is a carrier for other diseases. Please refer to the accompanying tables for residual carrier risks in individuals for the corresponding ethnic groups, assuming a negative family history and the patient is not affected with one of the diseases.

What is Smith-Lemli-Opitz Syndrome

Characteristic facial features, microcephaly, intellectual disability, and behavioral problems (e.g. autism). Abnormalities of the heart, lungs, kidneys, gastrointestinal tract, fingers/toes and genitalia are also common. Variable severity of symptoms.





Products

For Providers

For Patients

Research

Our Story

Products (Name Day Treat)

Peace of Mind

One test. 281 genetic disorders. Your peace of mind

Introducing Next Step. Guiding you to insights about your baby a development. The only screen backed with years of clinical research from Mount Sinar and researchers from around the world.



Need to register a kit?

Retros de la concessional Serros de la concessional Retros de la concessional Serros de la conce



THE END

WE LOOK FORWARD TO EXPLORING WAYS TO PARTNER!!!